ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
13.16
+0.08 (0.61%)
At close: Jul 26, 2024, 4:00 PM
13.13
-0.03 (-0.23%)
After-hours: Jul 26, 2024, 6:59 PM EDT
ADMA Biologics Revenue
ADMA Biologics had revenue of $81.88M in the quarter ending March 31, 2024, with 43.86% growth. This brings the company's revenue in the last twelve months to $283.18M, up 55.68% year-over-year. In the year 2023, ADMA Biologics had annual revenue of $258.22M with 67.59% growth.
Revenue (ttm)
$283.18M
Revenue Growth
+55.68%
P/S Ratio
10.77
Revenue / Employee
$453,808
Employees
624
Market Cap
3.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 258.22M | 104.13M | 67.59% |
Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
Dec 31, 2019 | 29.35M | 12.36M | 72.79% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 6.54B |
ICU Medical | 2.26B |
Concentra Group Holdings Parent | 1.85B |
LivaNova | 1.19B |
ACADIA Pharmaceuticals | 813.81M |
iRhythm Technologies | 513.17M |
Amicus Therapeutics | 423.49M |
TG Therapeutics | 289.33M |
ADMA News
- 2 months ago - ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 4 months ago - ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM® - GlobeNewsWire
- 5 months ago - ADMA Biologics to Participate in the Raymond James Institutional Investor Conference - GlobeNewsWire
- 5 months ago - ADMA Biologics Announces CFO Transition - GlobeNewsWire
- 5 months ago - ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 - GlobeNewsWire
- 5 months ago - ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics - GlobeNewsWire